BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1298 related articles for article (PubMed ID: 15156071)

  • 1. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
    J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
    J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
    J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.
    Dérand R; Montoni A; Bulteau-Pignoux L; Janet T; Moreau B; Muller JM; Becq F
    Br J Pharmacol; 2004 Feb; 141(4):698-708. PubMed ID: 14744818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid desensitization of receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) in chick cerebral cortex.
    Niewiadomski P; Nowak JZ; Sedkowska P; Zawilska JB
    Pol J Pharmacol; 2002; 54(6):717-21. PubMed ID: 12866731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of neuropeptides of the secretin/VIP/PACAP family on cyclic AMP formation in the chick hypothalamus and cerebral cortex.
    Nowak JZ; Kuba K; Zawilska JB
    Pol J Pharmacol; 2000; 52(6):467-71. PubMed ID: 11334241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
    Nilsson SF; De Neef P; Robberecht P; Christophe J
    Exp Eye Res; 1994 Apr; 58(4):459-67. PubMed ID: 7925682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.
    Pineau N; Lelievre V; Goursaud S; Hilairet S; Waschek JA; Janet T; Muller JM
    Neuropeptides; 2001 Apr; 35(2):117-26. PubMed ID: 11384207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on cyclic AMP formation in the hypothalamus and cerebral cortex of four avians and rat.
    Nowak JZ; Kuba K; Zawilska JB
    Pol J Pharmacol; 1999; 51(1):87-91. PubMed ID: 10389149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenylate cyclase-activating polypeptide type I receptors mediate cyclic AMP-dependent enhancement of neuronal acetylcholine sensitivity.
    Margiotta JF; Pardi D
    Mol Pharmacol; 1995 Jul; 48(1):63-71. PubMed ID: 7623776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.